The team at TAE Life Sciences is thrilled to unveil groundbreaking research that could transform the landscape of cancer care. A recent study, focusing on TAE Life Sciences’ Boronotyrosine (BTS) drug, a novel borylated amino acid analogue, has demonstrated exceptional potential to elevate the effectiveness of BNCT in combating cancer.
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, is thrilled to announce it is bringing BNCT to this year’s annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.
Dramatic advances in cancer treatment have completely transformed the landscape of cancer care in the last several decades.
TAE Life Sciences, a pioneering company in the field of cancer treatment, today announces the results from early testing of its TC440 boron-containing dipeptide compound for Boron Neutron Capture Therapy (BNCT).
TAE Life Sciences, a global leader in advanced biological-targeted radiation therapy, and creator of next-genera on boron neutron capture therapy (BNCT) systems, and the Franciszek Łukaszczyk Oncology Center (FLOC)
